Disease Area

Disease Area Metabolism & Diabetes

Tackling the Fatty-Liver Timebomb

| Jonathan James

Could modulation of fibroblast growth factor 21 translate into a new treatment for non-alcoholic fatty liver disease?

Disease Area Metabolism & Diabetes

IEM Identification

| Jonathan James

Combining metabolomics and DNA sequencing could be the key to discovering new inborn errors of metabolism in children.

Disease Area Pain & critical care

Painful Inequality?

| Jonathan James

How sex-dependent differences in molecular mechanisms could underpin men and women’s distinct experiences of chronic neuropathic pain.

Disease Area Cancer

Proving the worth of ICIs

| Jonathan James

New evidence points to the safety – and benefits – of immune checkpoint therapy in HIV-positive cancer patients

Disease Area Neurological

Neurons Under (Astroctyic) Attack

| Jonathan James

Could manipulation of micro-RNA cross-talk between astrocytes and neuronal cells yield a new therapeutic avenue for ALS?

Disease Area Cancer

Two-pronged Attack on Neuroblastoma

| Jonathan James

How inhibiting both polyamine synthesis (with DFMO) and uptake (with new small molecule AMXT 1501) could delay tumor development.

Disease Area Metabolism & Diabetes

Bite-size Breakthroughs: IELS, Imaging and Ocular Cancer

| Jonathan James

The latest advances in translational medicine – condensed into 20-second servings.

Disease Area Cancer

Gurus of Brain Oncology

| Jonathan James

Three leading lights in the neuro-oncology sphere explain what inspired them, how the field has evolved, and what challenges lie ahead.

Disease Area Cancer

Adaptive Invaders

| Jonathan James

New evidence suggests there’s more to metastasis than MMPs, demanding a therapeutic rethink.

Disease Area Metabolism & Diabetes

Grappling GK

| Jonathan James

How a new compound promises to selectively activate hepatic glucokinase in a bid to treat type 2 diabetes.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register